Ref: FOI/GS/ID 7767

04 November 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Advanced breast cancer.

You asked:
1) In the past 3 months, how many advanced/metastatic breast cancer patients have the status of;
a) HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]
b) HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]
2) In the past 3 months, how many breast cancer patients were treated with:
a.   Abemaciclib (Verzenios) + aromatase inhibitor *
b.   Abemaciclib (Verzenios) + Fulvestrant
c.   (Faslodex) Alpelisib (Piqray) + Fulvestrant (Faslodex)
d.   Atezolizumab (Tecentriq)**
e.   Bevacizumab (Avastin)
f.   Eribulin (Halaven)
g.   Everolimus (Afinitor) + Exemestane
h.   Fulvestrant (Faslodex) as a single agent
i.   Gemcitabine + paclitaxel
j.   Lapatinib (Tyverb)
k.   Neratinib (Nerlynx)
l.   Olaparib (Lynparza)
m.   Palbociclib (Ibrance) + aromatase inhibitor*
n.   Pertuzumab (Perjeta) + trastuzumab + docetaxel
o.   Ribociclib (Kisqali) + aromatase inhibitor*
p.   Ribociclib (Kisqali) + Fulvestrant (Faslodex)
q.   Talazoparib (Talzenna)
r.   Trastuzumab + paclitaxel Trastuzumab as a single agent
s.   Trastuzumab emtansine (Kadcyla)

t.   Trastuzumab Deruxtecan (Enhertu)
u.   Tucatinib + Trastuzumab + Capecitabine (Tukysa)
*v.   Other active systemic anti-cancer therapy ** *aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole **e.g. docetaxel, vinorelbine or capecitabine as a single agent*

Trust response:
1)
a) 0
b) 0

2)
a. 5
b. 3
c. 0
d. 4
e. 0
f. 2
g. 5
h. 2
i. 0
j. 0
k. 0
l. 0
m. 72
n. 4
o. 8
p. 0
q. 0
r. 36
s. 17
t. 1
u. 0
v. 212